Prelude Therapeutics Inc (PRLD) Stock Price, Quote & News

Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 467 1280

Website: preludetx.com

Address:

175 Innovation Boulevard, Wilmington, United States

mikesterz7 Feb. 3 at 11:35 PM

$PRLD Prelude Therapeutics said on Tuesday that the FDA gave clearances to proceed with early-stage trials for its experimental drug PRT12396.

0 · Reply

StocktwitsNews Feb. 3 at 10:12 PM

Why Did PRLD Stock Surge 13% Today? $PRLD $VTI $AVSC https://stocktwits.com/news/equity/markets/why-did-prld-stock-surge-today/cZb0IfKR4mY

0 · Reply

prismmarketview Feb. 3 at 7:21 PM

Prelude Therapeutics (NASDAQ: $PRLD) is on the move after the FDA cleared its IND for PRT12396, a mutant-selective JAK2V617F inhibitor for myeloproliferative neoplasms, enabling a Phase 1 trial under an exclusive option partnership with Incyte and marking a key clinical inflection point for this precision oncology name. https://prismmarketview.com/prelude-therapeutics-secures-fda-clearance-for-incyte-partnered-cancer-study/

0 · Reply

Jaybird827 Feb. 3 at 5:07 PM

$PRLD god news, Maybe we are moving in the right direction. 🤞🏼

0 · Reply

notreload_ai Feb. 3 at 4:22 PM

$PRLD receives FDA clearance to begin testing PRT12396, a targeted therapy for myeloproliferative neoplasms affecting thousands of patients. https://notreload.xyz/prelude-therapeutics-gets-fda-green-light-for-groundbreaking-blood-cancer-treatment/

0 · Reply

moosegoose Feb. 3 at 2:31 PM

$PRLD excellent news. Back to $3 soon

0 · Reply

MrTicker Feb. 3 at 2:04 PM

$PRLD Prelude Therapeutics Gets FDA Clearance Of Investigational New Drug Application For PRT12396 BENZINGA 8:03 AM ET 2/3/2026

0 · Reply

MrTicker Feb. 3 at 2:01 PM

$PRLD Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F InhibitorPhase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 GLOBENEWSWIRE 8:00 AM ET 2/3/2026

0 · Reply

LabPsycho Feb. 2 at 2:56 PM

$PRLD This thing trades like there are only half a dozen holders in it - dont any body sneeze, it could move +/-30%

1 · Reply

allyboy Jan. 28 at 9:23 PM

$PRLD this has been so boring that i forgot i still owned it....:)

0 · Reply

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

Dec 6, 2025, 11:00 AM EST - 2 months ago

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

Nov 26, 2025, 11:10 AM EST - 2 months ago

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Nov 12, 2025, 8:31 PM EST - 2 months ago

Prelude Therapeutics Incorporated (PRLD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:01 AM EST - 2 months ago

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 11, 2025, 11:24 PM EST - 2 months ago

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

Nov 4, 2025, 7:05 AM EST - 3 months ago

Prelude Therapeutics Announces Strategic Business Update

Nov 4, 2025, 7:01 AM EST - 3 months ago

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Nov 3, 2025, 9:01 AM EST - 3 months ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Oct 17, 2025, 7:30 AM EDT - 3 months ago

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

Aug 14, 2025, 7:00 AM EDT - 6 months ago

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 2, 2025, 7:30 AM EDT - 8 months ago

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

May 6, 2025, 4:05 PM EDT - 9 months ago

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 1, 2025, 7:30 AM EDT - 9 months ago

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Apr 25, 2025, 4:05 PM EDT - 10 months ago

Prelude Announces Presentations at 2025 AACR Annual Meeting

Mar 10, 2025, 7:30 AM EDT - 11 months ago

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Mar 5, 2025, 7:30 AM EST - 11 months ago

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

$Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies$

Dec 11, 2024, 7:30 AM EST - 1 year ago

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Nov 27, 2024, 7:30 AM EST - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Sep 13, 2024, 10:00 AM EDT - 1 year ago

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Aug 12, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

May 9, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

May 7, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 9, 2024, 4:35 PM EDT - 1 year ago

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Mar 5, 2024, 4:45 PM EST - 2 years ago

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Feb 29, 2024, 4:05 PM EST - 2 years ago

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Feb 15, 2024, 4:05 PM EST - 2 years ago

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Dec 11, 2023, 9:34 AM EST - 2 years ago

Prelude Therapeutics Announces $25 Million Private Placement

Nov 1, 2023, 4:10 PM EDT - 2 years ago

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Aug 29, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

May 31, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 17, 2023, 4:08 PM EDT - 2 years ago

Prelude Therapeutics Announces Launch of Proposed Public Offering

May 8, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Apr 27, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Apr 11, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Mar 15, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Feb 9, 2023, 9:05 AM EST - 3 years ago

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Nov 14, 2022, 8:00 AM EST - 3 years ago

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Aug 9, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

May 10, 2022, 8:00 AM EDT - 4 years ago

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Mar 16, 2022, 7:30 AM EDT - 4 years ago

Prelude Therapeutics Reports Full Year 2021 Financial Results

Mar 11, 2022, 8:00 AM EST - 4 years ago

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

mikesterz7 Feb. 3 at 11:35 PM

$PRLD Prelude Therapeutics said on Tuesday that the FDA gave clearances to proceed with early-stage trials for its experimental drug PRT12396.

0 · Reply

StocktwitsNews Feb. 3 at 10:12 PM

Why Did PRLD Stock Surge 13% Today? $PRLD $VTI $AVSC https://stocktwits.com/news/equity/markets/why-did-prld-stock-surge-today/cZb0IfKR4mY

0 · Reply

prismmarketview Feb. 3 at 7:21 PM

0 · Reply

Jaybird827 Feb. 3 at 5:07 PM

$PRLD god news, Maybe we are moving in the right direction. 🤞🏼

0 · Reply

notreload_ai Feb. 3 at 4:22 PM

0 · Reply

moosegoose Feb. 3 at 2:31 PM

$PRLD excellent news. Back to $3 soon

0 · Reply

MrTicker Feb. 3 at 2:04 PM

$PRLD Prelude Therapeutics Gets FDA Clearance Of Investigational New Drug Application For PRT12396 BENZINGA 8:03 AM ET 2/3/2026

0 · Reply

MrTicker Feb. 3 at 2:01 PM

0 · Reply

LabPsycho Feb. 2 at 2:56 PM

$PRLD This thing trades like there are only half a dozen holders in it - dont any body sneeze, it could move +/-30%

1 · Reply

allyboy Jan. 28 at 9:23 PM

$PRLD this has been so boring that i forgot i still owned it....:)

0 · Reply

allyboy Jan. 27 at 3:51 PM

$PRLD Looking at volume, does anyone know this still exists? :)

1 · Reply

peepthestamp Jan. 24 at 7:36 AM

$PRLD

0 · Reply

SteelcityTrader44 Jan. 22 at 5:11 PM

$PRLD Well that was a good shakeout past couple weeks.

0 · Reply

Jaybird827 Jan. 22 at 3:50 PM

$PRLD up down up down

0 · Reply

Dizzier47 Jan. 20 at 3:48 PM

$PRLD either a +10% or a -10% here i love gambling

0 · Reply

OfficialStocktwitsUser Jan. 15 at 6:57 PM

$PRLD RSI: 48.60, MACD: 0.1224 Vol: 0.32, MA20: 2.43, MA50: 1.91 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

LabPsycho Jan. 12 at 6:50 PM

$FHTX $PRLD @Stmkr mysteriously prld pause smarca2 = 100% price increase. Something else seems to be going on? I've posted my conspiracy theories for rebuking. Worst part is all the time I wasted creating a simulation with their molecule. Maybe I should work on a molecular model for FHTX...however such a huge time and effort drain in the research and set up required to get one to work and hardly anyone seems to care about these molecular dynamic simulations I post. Hmm...what to do?

1 · Reply

Olg59 Jan. 12 at 5:19 PM

$PRLD Indian CEO...

0 · Reply

Stmkr Jan. 10 at 5:38 AM

$FHTX Surprisingly good cash raise. But I am skeptical of their lead SMARCA2 program following prior failures, including pausing of SMARCA2 program by $PRLD

2 · Reply

SteelcityTrader44 Jan. 6 at 9:58 PM

$PRLD Are the weak hands out yet or do we have to retest 2?

0 · Reply

Jaybird827 Jan. 6 at 9:34 PM

$PRLD what’s going on with this stock?

0 · Reply

kubota2323 Dec. 31 at 4:52 PM

$PRLD shake that tree

0 · Reply

Market Cap	116.30M
Revenue (ttm)	7.00M
Net Income (ttm)	-127.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,816.71%
Debt to Equity Ratio	0.00

Volume	725,600
Avg Vol	469,364
Day's Range	N/A - N/A
Shares Out	62.87M
Stochastic %K	46%
Beta	0.90
Analysts	Strong Sell
Price Target	$4.00